BioCentury | Jan 10, 2020
Emerging Company Profile

NorthSea: Engineering fatty acids for NASH

...developing that acumen for over 10 years.” Canadian biotech Liminal BioSciences Inc. (TSX:LMNL; NASDAQ:LMNL), formerly known as Prometic Life Sciences...
BioCentury | Dec 20, 2018
Company News

Management tracks: Prometic, Synlogic

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) board member and CEO Pierre Laurin stepped down to pursue other opportunities. Chairman Simon Best was named interim CEO while the fibrosis and orphan disease company searches for a...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...Inc. (NASDAQ:PTLA) AndexXa andexanet alfa Reverse anticoagulant activity of Factor Xa inhibitors PDUFA date 5/4/18 Prometic Life Sciences...
BioCentury | Apr 3, 2018
Company News

Management tracks: Abeona, Dermavant, Assembly

...was VP of manufacturing operations at Endo International plc (NASDAQ:ENDP). Fibrosis and orphan disease company Prometic Life Sciences...
BioCentury | Mar 2, 2018
Clinical News

Prometic discontinues Phase II of PBI-4050 to treat cystic fibrosis related diabetes

...HbA1C following oral glucose tolerance test, change from baseline in pulmonary function parameters and weight. Prometic...
...PBI-4050 to treat IPF is slated to begin mid-year. PBI-4050 is an oral anti-fibrotic compound. Prometic Life Sciences...
...change from baseline in pulmonary function parameters and weight Status: Phase II discontinued Milestone: NA Sandi Wong PBI-4050 PBI-4425 PBI-4547 Prometic Life Sciences...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...NASDAQ:PGNX) Azedra iobenguane I 131 Malignant recurrent and/or unresectable pheochromocytoma and paraganglioma PDUFA date 4/30/18 Prometic Life Sciences...
BioCentury | Nov 30, 2017
Clinical News

Prometic reports Phase II data for PBI-4050 in Alstrom syndrome

...In September, Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) reported data from 8 patients with Alstrom syndrome in a...
...IPF). The product has promising innovative medicine (PIM) designation from MHRA to treat Alstrom syndrome. Prometic Life Sciences...
...global metabolome, microdialysate fractions, liver stiffness and fat content Status: Phase II data Milestone: NA Claire Quang PBI-4050 Prometic Life Sciences...
BioCentury | Oct 13, 2017
Company News

Priority Review for Prometic’s plasminogen therapy

...rare pediatric disease designations from FDA. Prometic gained C$0.08 to C$1.64 in Toronto on Friday. Alicia Parker Ryplazym Prometic Life Sciences...
BioCentury | Sep 27, 2017
Company News

Management tracks: Gilead, Tango, Rubius, Bicycle

...diseases play Eloxx Pharmaceuticals Ltd. (Rehovot, Israel) named Gregory Weaver CFO. He was CFO at Prometic Life Sciences...
BioCentury | Sep 1, 2017
Clinical News

Prometic's Ryplazim gets rare pediatric disease designation

...human plasma-derived plasminogen also has Orphan Drug and Fast Track designations from FDA. Last December, Prometic...
...treat congenital plasminogen deficiency. If approved, the company expects to launch the product in 1Q18. Prometic Life Sciences...
...Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Product: Ryplazim ( Ryplazym , human plasma-derived plasminogen) Business: Hematology Meghan Sullivan Ryplazym Prometic Life Sciences...
Items per page:
1 - 10 of 144
BioCentury | Jan 10, 2020
Emerging Company Profile

NorthSea: Engineering fatty acids for NASH

...developing that acumen for over 10 years.” Canadian biotech Liminal BioSciences Inc. (TSX:LMNL; NASDAQ:LMNL), formerly known as Prometic Life Sciences...
BioCentury | Dec 20, 2018
Company News

Management tracks: Prometic, Synlogic

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) board member and CEO Pierre Laurin stepped down to pursue other opportunities. Chairman Simon Best was named interim CEO while the fibrosis and orphan disease company searches for a...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...Inc. (NASDAQ:PTLA) AndexXa andexanet alfa Reverse anticoagulant activity of Factor Xa inhibitors PDUFA date 5/4/18 Prometic Life Sciences...
BioCentury | Apr 3, 2018
Company News

Management tracks: Abeona, Dermavant, Assembly

...was VP of manufacturing operations at Endo International plc (NASDAQ:ENDP). Fibrosis and orphan disease company Prometic Life Sciences...
BioCentury | Mar 2, 2018
Clinical News

Prometic discontinues Phase II of PBI-4050 to treat cystic fibrosis related diabetes

...HbA1C following oral glucose tolerance test, change from baseline in pulmonary function parameters and weight. Prometic...
...PBI-4050 to treat IPF is slated to begin mid-year. PBI-4050 is an oral anti-fibrotic compound. Prometic Life Sciences...
...change from baseline in pulmonary function parameters and weight Status: Phase II discontinued Milestone: NA Sandi Wong PBI-4050 PBI-4425 PBI-4547 Prometic Life Sciences...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...NASDAQ:PGNX) Azedra iobenguane I 131 Malignant recurrent and/or unresectable pheochromocytoma and paraganglioma PDUFA date 4/30/18 Prometic Life Sciences...
BioCentury | Nov 30, 2017
Clinical News

Prometic reports Phase II data for PBI-4050 in Alstrom syndrome

...In September, Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) reported data from 8 patients with Alstrom syndrome in a...
...IPF). The product has promising innovative medicine (PIM) designation from MHRA to treat Alstrom syndrome. Prometic Life Sciences...
...global metabolome, microdialysate fractions, liver stiffness and fat content Status: Phase II data Milestone: NA Claire Quang PBI-4050 Prometic Life Sciences...
BioCentury | Oct 13, 2017
Company News

Priority Review for Prometic’s plasminogen therapy

...rare pediatric disease designations from FDA. Prometic gained C$0.08 to C$1.64 in Toronto on Friday. Alicia Parker Ryplazym Prometic Life Sciences...
BioCentury | Sep 27, 2017
Company News

Management tracks: Gilead, Tango, Rubius, Bicycle

...diseases play Eloxx Pharmaceuticals Ltd. (Rehovot, Israel) named Gregory Weaver CFO. He was CFO at Prometic Life Sciences...
BioCentury | Sep 1, 2017
Clinical News

Prometic's Ryplazim gets rare pediatric disease designation

...human plasma-derived plasminogen also has Orphan Drug and Fast Track designations from FDA. Last December, Prometic...
...treat congenital plasminogen deficiency. If approved, the company expects to launch the product in 1Q18. Prometic Life Sciences...
...Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Product: Ryplazim ( Ryplazym , human plasma-derived plasminogen) Business: Hematology Meghan Sullivan Ryplazym Prometic Life Sciences...
Items per page:
1 - 10 of 144